Raumedic, a medical technology manufacturer, has launched a new home use device, named Raumed Home ICP, for intracranial pressure (ICP) monitoring. The product was developed for patients suffering from hydrocephalus, a condition in which excessive amounts of cerebrospinal fluid (CSF) is accumulated in the brain. The device has recently received CE marking.

For neuro-monitoring, a telemetric catheter is implanted in the patient’s cranium in a 20-minute procedure, allowing intracranial pressure to be directly measured from the brain’s tissue. A circular reader antenna is then placed above the catheter to register and store the data. During the measurement, the patient is able to freely move in their home environment and select or store certain activities or events on the handheld device, such as headaches, sleeping, eating, and nausea, with the touch of a button.

There are numerous ICP monitoring devices currently on the market. ICP monitoring using an external ventricular drainage (EVD) device is considered the gold standard. This technique involves the surgical insertion of a catheter into the ventricles of the brain, which allows measurement and CSF drainage. However, this method is not ideal for patients with small ventricles or patients with brain swelling. Additionally, the long-term usage of EVDs can increase the risk of intracranial infection. Monitoring directly from the tissue of the brain is considered more accurate and with lower incidence of infection and bleeding.

GlobalData predicts the ICP monitoring devices market will reach $181.9M by 2025, growing at a CAGR of 2.4%. The launch of the Raumed Home ICP is expected to disrupt the market, giving neurosurgeons better insights for therapy and allowing hydrocephalus patients to lead a more active life.